**Name of journal: *World Journal of Stem Cells***

**ESPS Manuscript NO: 13688**

**Columns: REVIEW**

**Corneal stem cells and tissue engineering: Current advances and future perspectives**

de Araujo AL *et al*. Current advances in corneal stem cells

Aline Lütz de Araujo, José Álvaro Pereira Gomes

**Aline Lütz de Araujo,** Clínica Lentecer, Porto Alegre - RS 90570041, Brazil

**José Álvaro Pereira Gomes,** Department of Ophthalmology and Visual Sciences, Universidade Federal de São Paulo, São Paulo – SP 04023062, Brazil

**Author contributions:** de Araujo AL and Gomes JAP equally contributed to this paper.

**Conflict-of-interest:** The authors declare no potential conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Aline Lütz de Araujo, MD,** Clínica Lentecer, Rua Doutor Timóteo, 727/801, Porto Alegre - RS 90570041, Brazil. alinelutz.a@gmail.com

**Telephone:** +55-51-30227600

**Fax:** +55-51-33388080

**Received:** August 29, 2014

**Peer-review started:** August 30, 2014

**First decision:** December 17, 2014

**Revised:** January 5, 2015

**Accepted:** April 16, 2015

**Article in press:**

**Published online:**

**Abstract**

Major advances are currently being made in regenerative medicine for cornea. Stem cell-based therapies represent a novel strategy that may substitute conventional corneal transplantation, albeit there are many challenges ahead given the singularities of each cellular layer of the cornea. This review recapitulates the current data on corneal epithelial stem cells, corneal stromal stem cells and corneal endothelial cell progenitors. Corneal limbal autografts containing epithelial stem cells have been transplanted in humans for more than 20 years with great successful rates, and researchers now focus on *ex vivo* cultures and other cell lineages to transplant to the ocular surface.  A small population of cells in the corneal endothelium was recently reported to have self-renewal capacity, although they do not proliferate *in vivo*. Two main obstacles have hindered endothelial cell transplantation to date: culture protocols and cell delivery methods to the posterior cornea *in vivo*.  Human corneal stromal stem cells have been identified shortly after the recognition of precursors of endothelial cells. Stromal stem cells may have the potential to provide a direct cell-based therapeutic approach when injected to corneal scars. Furthermore, they exhibit the ability to deposit organized connective tissue *in vitro* and may be useful in corneal stroma engineering in the future. Recent advances and future perspectives in the field are discussed.

**Key words:** Cornea; Stem cells; Cell-based therapy; Limbal transplantation; tissue engineering; Corneal endothelium

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Corneal stem cell-based therapies represent a novel strategy that may substitute conventional corneal transplantation, albeit there are many challenges ahead given the singularities of each cellular layer of the cornea. To date, the most widespread clinical approach to regenerative medicine in the eye has been the utilization of limbal stem cells for ocular surface diseases. New therapeutic strategies are under development due to the recent identification of corneal stromal stem cells and corneal endothelial cell progenitors. This review recapitulates the current advances and discusses future perspectives in the field.

de Araujo AL, Gomes JAP. Corneal stem cells and tissue engineering: Current advances and future perspectives. *World J Stem Cells* 2015; In press

**INTRODUCTION**

The human cornea consists of 5 recognized layers, 3 of them are cellular (epithelium, stroma and endothelium) and 2 are interface layers (Bowman’s layer and Descemet membrane)[1]. Corneal epithelium is a stratified, non-keratinizing squamous layer characterized by extreme uniformity from limbus to limbus[2]. Epithelial cells are regularly shed from the surface and replaced by new cells that are ultimately provided by stem cells located at the limbal area of the peripheral cornea[2]. Corneal stroma provides the bulk of the structural framework of the cornea and comprises approximately 80% to 90% of its thickness. Keratocytes are the major cell type of the stroma and are involved in maintaining its extracellular matrix[1]. An intricate collagen network in the extracellular matrix accounts for the cornea’s shape, stability, mechanical strength and transparency[3]. Posteriorly, a thin monolayer of polygonal cells constitutes the corneal endothelium. Since it is in contact with the aqueous humor, the endothelium regulates corneal hydration through active cell pumps, thereby being crucial to maintain corneal transparency[4]. Except for oxygen, all corneal nutrients come from the aqueous humor through endothelial cells[5].

Regenerative medicine for the cornea represents a novel treatment strategy for patients with corneal diseases. Enormous promise has been ascribed to this modality because it offers a paradigm shift from conventional corneal transplantation to stem cell-based therapeutic strategies[6]. Cellular therapies are challenging given the singularities of each cellular layer of the cornea. To date, the most widespread clinical approach to regenerative medicine in the eye has been the utilization of limbal stem cells for ocular surface diseases. In 1989, Kenyon and Tseng reported successful autologous transplantation of limbal tissue from the healthy fellow eye in 26 cases of unilateral limbal stem cell deficiency[7]. Many reports and studies of limbal stem cell transplantation have followed, from heterologous donors to *ex vivo* cellular cultures.

In the present article, we discuss the current status in corneal stem cell research and the perspectives regarding corneal regenerative therapies and tissue engineering.

**CORNEAL EPITHELIUM**

Corneal epithelial stem cells are located at the corneoscleral limbus and are the ultimate source for regeneration of the entire corneal epithelium under normal and injured states[2,8,9]. Multiple diseases that destroy the limbal epithelial stem cell, its environment, or a combination of both can lead to a clinical condition known as limbal stem cell deficiency (LSCD)[10]. The clinical picture of LSCD is a conjunctivalized corneal surface with neovessels and recurrent or persistent epithelial defects[11]. As a result, patients with LSCD have decreased vision, photophobia, tearing, and recurrent pain episodes[2,11,12].

The classic limbal stem cell transplantation procedure involves grafting of a healthy limbal biopsy onto the recipient corneal surface. The technique was developed in the late 1980s and early 1990s and proved useful in LSCD[13]. Limbal grafts are obtained either from an unaffected fellow eye[7,14], from a live relative[14,15] or from cadaveric donors[14,16,17]. For patients inflicted with unilateral total LSCD, where the entire limbal circumference is damaged in only one eye, transplantation of limbal stem cells from the fellow eye has shown success rates greater than 80%[18,19]. Due to the autologous source of cells, there is no risk of immune rejection in these cases. Concerns regarding irreversible changes that may occur at the limbal site of the donor eye, as reported in rabbits[20,21], prompted clinicians to consider cadaveric donors. However, in this procedure, there is an increased risk of allograft rejection and therefore systemic immunosuppression is mandatory[14,16,17]. Although larger grafts can be procured from cadaveric eyes (360 ring grafts), a recent study[22] found living-related limbal allografts to have better results in terms of vision gain and ocular surface restoration than cadaveric keratolimbal allografts. In a series of 39 eyes that received keratolimbal allografts from cadaveric donors, the overall survival of ambulatory vision, namely 20/200 or better, was 53.6% at 3 years, but a progressive decline of the visual outcome and graft survival became evident with time[23]. The failure of the graft is related to loss of donor cells overtime, probably due to recipient’s preoperative conditions such as dry eye and/or lid abnormalities, persistent inflammation or postoperative asymptomatic and progressive allograft rejection[23].

Regardless of the source of epithelial stem cells, amniotic membrane transplantation (AMT) has been widely used in an attempt to improve limbal grafts success[24–26]. Nevertheless, a recent study interestingly showed no differences in the outcomes of chemically injured eyes treated with or without AMT as an adjunctive procedure to limbal transplantation[27]. Amniotic membrane is a biologic, avascular tissue with anti-angiogenic, anti-scarring and anti-inflammatory characteristics[28,29]. Since the process of conjunctivalization in LSCD is invariably associated with destruction of the basement membrane[10], amniotic membrane transplanted onto the corneal surface facilitates epithelial expansion *in vivo*. Amniotic membrane has a thick basement membrane that serves as a substrate upon which epithelial cells can migrate and regenerate to form new and healthy tissue[28]. In cases of partial LSCD, AMT has been successfully used alone, without stem cell transplantation[30]. Amniotic membrane can also be used as a biologic bandage in the acute phase of inflammatory disorders, such as ocular burns[31,32] and Stevens-Johnson syndrome[33-36], in order to prevent development of LSCD and other surface complications. Nevertheless, most of the studies are non-comparative, and a clinical trial that addressed the potential benefits of AMT did not find definite advantage of early AMT over conservative medical treatment in preventing scarring sequelae in eyes with chemical burns[37].

With the development of cell therapy, amniotic membrane began to be employed in *ex vivo* expansion of limbal stem cells or their progeny[38]. Pellegrini and colleagues published the first clinical report in the field of tissue engineering for the cornea in 1997[39]. They reported an autologous cultivated epithelial cell transplantation that successfully restored the ocular surface in 2 cases of LSCD due to chemical burns. Other series of cultivated epithelial limbal transplantation (CLET) have followed[38,40–46] and efforts to culture corneal cells *in vitro* are currently being made in different centers worldwide. Protocols use either an explant or cell suspension for culturing progenitor cells. The benefits of using explants are that they are easy to prepare and there is no danger of damaging the donor’s corneal epithelium through enzyme exposure[40]. However, limbal stem cells may poorly migrate from the limbal explants onto the carrier[40,47]. Some protocols include co-cultivation with murine 3T3 feeder layers[48], which are believed to promote niche regulation of limbal stem cells and thus delay epithelial differentiation[49]. The use of animal-derived products carries a theoretical risk of infection, rejection or acquisition of prion diseases[50]. By using autologous human serum instead of fetal bovine serum[51] and eliminating feeder cells, complete xenofree cultivation for CLET is possible[52].

A novel possibility for delivering limbal stem cells on the corneal surface is to use contact lens as a carrier and as a substrate for cell expansion. Two studies with animal models of LSCD reported promising results with contact lens delivery, as stem cells retained their phenotype and mitotic activity after being transferred to the ocular surface[53,54]. Furthermore, the seeded contact lenses were easy to manipulate and its material is nonimmunogenic[54].

We perform transplantation of other cell lineages onto the ocular surface for LSCD when total LSCD occurs bilaterally and therefore no autologous tissue for CLET is available. Conjunctival epithelial cells are the most akin biologically to corneal epithelial ones in the human body and our group has successfully cultivated and transplanted them for ocular surface reconstruction[55]. Use of non-ocular surface epithelial cells was first made with cultivated oral mucosal epithelial transplantation in rabbits[56] and application of this technique in humans has followed thereafter[57–65]. Both conjunctival and oral mucosal epithelial cells are not expected to differentiate into corneal epithelial cells, like stem cells would. However, most studies show adequate functionality of the grafts, giving them clinical relevance in tissue engineering.

A promising source of stem cells for ocular therapy is the human deciduous teeth. These undifferentiated cells exhibit all characteristics of pluripotent adult stem cells and continuously express markers of limbal stem cells[66]. Tissue-engineered sheets of dental-pulp stem cells were effective for cornea reconstruction in a rabbit model of chemical burn[67]. Other recently proposed sources of stem cells for cornea epithelium are hair follicle[68], bone marrow[69,70] and umbilical cord[71]. It has been demonstrated that adult tissue-specific stem cells have the ability to differentiate into lineages other than the tissue of origin[72].

**CORNEAL STROMA**

One of the most challenging steps in engineering human corneal tissue is to produce the corneal stroma, given the difficulty in reproducing its highly ordered hierarchical ultrastructure, which relates to its exceptional biomechanical properties and optical transparency[73]. Keratocytes are native resident cells of the corneal stroma and are responsible for maintaining the extracellular matrix (ECM)[1]. The bulk of the stroma comprises approximately 200 orthogonally oriented lamellae, and each of them is made up of long uniform collagen fibrils lying parallel one to another with regular inter-fibril spacing[74,75]. Under *in vitro* expansion in serum containing media, keratocytes lose their phenotype and soon become fibroblastic. Unlike keratocytes, fibroblasts secrete a disorganized ECM typically found in opaque corneal scars[76–78]. Even in serum-free conditions, primary keratocytes maintain an *in vivo* phenotype through some population doublings, but lose their morphology, gene expression, and the ability to organize a cornea-like ECM after greater expansion[79]. A more recent study, however, demonstrated that corneal fibroblasts respond to a specific pattern of topographical cues from the substratum and regain differentiation potential, thus being able to secrete highly organized ECM typical of corneal stroma[79].

Recently, Du and coworkers identified the first human cells with keratocyte progenitor potential in the corneal stroma[80]. This small population of cells exhibited properties of stem cells, such as clonal growth *in vitro*, extended lifespan, and the ability to differentiate into several different cells types, including keratocytes of the cornea. When cultured as floating pellets in the absence of rigid scaffolding or substratum, in a serum-free medium, the human corneal stromal stem cells (hCSSCs) differentiate into cells expressing a gene profile similar to that of human keratocytes and deposit tissue-like ECM with a composition and structure similar to that of the corneal stroma[81]. A comparative study showed that, under the same culture conditions, human corneal fibroblasts tended to differentiate into myofibroblasts and deposited a less-organized collagen-fibrillar construct, while hCSSCs successfully differentiated into keratocytes and secreted multilayered lamellae with orthogonally-oriented collagen fibrils, in a pattern mimicking human corneal stromal tissue[73]. This *in vitro* secretion of stromal-like connective tissue points to a potential use of hCSSCs in tissue bioengineering. An interesting finding is that hCSSC may exhibit immune privilege: injected into mice corneas with scars, these cells did not elicit immune T-cell response[82], as it would be expected in a xenotransplantation model. As a matter of fact, a successful restoration of corneal organization and transparency was achieved after the injection[82]. Therefore, besides the utility in bioengineering stromal tissue, hCSSC may have the potential to provide a direct cell-based therapeutic approach[83].

Other engineering strategies for the corneal stroma include animal sources as a substitute of native tissue. Once rejection is a major obstacle to widespread use of xenotransplantation, fully acellular corneas have been proposed to overcome immune rejection. A decellularized animal tissue provides a three-dimensional ECM structure, favorable biocompatibility, adequate biomechanical tension and high transparency that mimics the native cornea and can be applied with or without the addition of a cellular component[13]. Most studies use porcine corneas[84–87], but other sources such as cow[88] and cat[89] are amenable for xenotransplantation. Since decellularized corneal stroma retains basement membrane components, it was used as a matrix scaffold for limbal stem cell expansion *in vitro*, and as a carrier for epithelial transplantation in animal models, with good results[90,91]. Decellularization may be applied not only to xenogeneic, but also to allogeneic cornea tissues for transplantation. Theoretically, this would reduce the complications associated with allogeneic corneal transplants and improve the clinical outcomes.

**CORNEAL ENDOTHELIUM**

Corneal endothelium is a monolayer of cells that maintains a nonproliferative state, with cell density decreasing steadily under normal circumstances throughout life[92,93]. It has been for long believed that they do not replace themselves once they are lost in aging or diseases. On the contrary of corneal epithelial cells, which readily and continuously divide from limbal stem cells, corneal endothelial cells fail to expand *in vivo*, and expand slowly *in vitro*[94,95]. Accumulating evidence, however, points to the existence of a dormant progenitor cell population located in the posterior limbus, the transitional area from the periphery of the endothelium and Schwalbe’s line to the anterior portion of the trabecular meshwork. These putative progenitor cells are likely to be capable of producing both endothelial and trabecular cells[96]. Identification of a circumferential and discontinuous cord of cells with unusual ultrastructural features along the Schwalbe’s line in monkeys dates from 1982[97]. Attention to these cells was drawn later, when repopulation of trabecular cells after argon laser trabeculoplasty was reported[98,99]. Possibly, these cells are invigorated and proliferate after laser trabeculoplasty through the release of growth factors and cytokines[96].

There is substantial evidence that the human corneal endothelium cells hold different characteristics according to their position in the cornea. Stained corneas revealed that cell density at the peripheral inner cornea, up to 1.6 mm from Schwalbe line, is about 30% higher than in the central cornea[100]. Additionally, specular microscopy documented the uneven cell distribution from center to periphery *in vivo*[101]. The reason for this difference is not known, albeit it has been suggested that the peripheral cornea may provide a physiologic reserve and storage region of endothelial cells for continuous, lifetime cellular supply for the central cornea[101]. Bednarz and coworkers showed that cells isolated from the central part are densely packed and exhibit no mitogenic activity, while cells derived from the peripheral part of the cornea are characterized by mitogenic activity but their cell-to-cell attachment seems to be less tight than *in vivo*[102]. Konomi *et al*[103] studied human donor corneas with different donor ages and found that cells from both the central and peripheral areas retain potential proliferative capacity, although the doubling time tended to be higher for cells from the central cornea and from older donors.

Data from molecular marker studies provide support for the existence of a stem-like cell niche at the corneal endothelium. Dissected endothelial tissues from human and rabbits exhibited positive telomerase activity in the peripheral and intermediate sections, but no activity was observed in the central endothelial tissues or the limbus between the trabecular meshwork and Schwalbe’s line[104]. Telomerase activity is a characteristic marker for transient amplifying cells. The same study also tested endothelial cells for alkaline phosphatase-catalyzed bromodeoxyuridine (BrdU) labeling, which demonstrates cell division. In the case of rabbit corneal endothelium, which is known to divide with regularity, BrdU staining was always seen following a mechanical wound, but in the human corneal endothelium, staining only occurred at the wound site in 10% of the corneas tested[104]. Such results corroborate a typical lack of propensity toward cell division in wounding response in the human endothelium. Another cellular marker for proliferation is Ki67, which is detected in the nucleus of proliferating cells. Ki67 antibody staining produces characteristic patterns depending on cell position within the cycle, so it makes possible to quantify cell cycle entry and completion *in vitro*[105]. Stem cell markers that were also identified in the posterior limbus cells are nestin and alkaline phosphatase[106]. Human corneal endothelial cell precursors have been isolated using the sphere-forming assay and expressed markers of the mesenchymal (-smooth muscle actin) and neural (3-tublin, glial fibrillary acidic protein) lineages, although none of these are specific markers of endothelial cells or their progenitors[107]. More recently, two monoclonal antibodies taken together, anti-GPC4 and anti-CD200, were found to stain HCECs with specificity[108]. The finding is useful for purification of cultures that may be contaminated by stromal fibroblasts. Since the endothelial cells are not expected to proliferate *in vivo*, isolation and stimulation of cell division *in vitro* is an important step towards cell replacement therapy[109].

Human corneal endothelial cells proliferate and replicate under special conditions. In medium containing fetal bovine serum and fibroblast growth factor, cells from older donors proliferated but responded more slowly and to a lesser extent than cells from younger donors. When epidermal growth factor added to the medium, cells from older donors were stimulated to enter the cell cycle faster and the amount of actively cycling cells and mitotic figures increased[105]. An important factor to activate endothelial cell cycle is the disruption of cell-cell contact. Zhu and colleagues demonstrated that maturation of intercellular adherent junctions correlates with a rapid decline of the proliferative potential in endothelial cell monolayers during cultivation[110]. To overcome that, EDTA solution was used in an organ culture model once it has the ability to release endothelial cells from cell–cell contact. After treatment of the intact endothelial monolayer with EDTA, approximately 17% of the cell population entered the cell cycle[111]. The use of EDTA alone, rather than a trypsin/EDTA solution to digest cells, may afford a greater cell survival rate[112]. Also, the presence of L-ascorbic acid 2-phosphate (Asc-2P) in the culture was found to increase the proliferation of endothelial cells. Asc-2P is an antioxidant derivative of Asc that upregulates hepatocyte growth factor production *in vitro*[113].

Further advance is required for the delivering method. Different cell carriers have been tested in animal models, and the main challenges are to achieve biomaterial transparency, structural strength and integration with native tissues[13,114]. One approach to deliver cultured endothelial cells through direct injection employed magnetic attraction to attach cells to the Descemet’s membrane, thus preventing them to disperse in the anterior chamber[115]. Mimura *et al*[115,116] incorporated iron powder spheres in rabbit corneal endothelial cells and a neodymium magnet was placed anterior to the eyelid to attract the particles after cell suspension injection. They demonstrated that the use of 5-10 micromoles of iron powder solution was associated with good cell survival rate and 12 mo later no noticeable toxicity was present. Since rabbit’s endothelial cells are able to regenerate spontaneously, a control group that had been submitted to the same corneal injury did not receive the cell injection. The control group showed signs of endothelial failure. Magnetic field was later used in a human *ex vivo* model. Superpara-magnetic microspheres were incorporated into the cytoplasm of human corneal endothelial cells and facilitated cell migration and attachment without affecting cell viability or light transmittance[117]. Toxicity to cells and other ocular tissues from magnetite oxide particles is a concern though, and safety remains to be demonstrated. Such compounds are used as magnetic resonance imaging contrast agents, on which safety and efficacy studies have been conducted, but the toxicity profile of this agent is likely to be different when delivered to the anterior segment of the eye.

 The literature to date supports that the putative endothelial cells progenitors are precursors, not stem cells *per se*. Common features of precursors and adult stem cells are that both have self-renewal capacity and the ability to differentiate into mature effector cells, but stem cells can renew themselves indefinitely and produce one or more progenies through symmetric and asymmetric division, whereas progenitor cells have limited self-renewal capacity and more restricted differentiation abilities[96,107].

**CONCLUSION**

Progress in corneal stem cell research provides an optimistic prospect on their use in regenerative medicine and tissue engineering. In this paper, we presented different limbal transplantation techniques, using either autologous or heterologous source of limbal stem cells, and the epithelial cells cultivated *in vitro* that are being successfully transplanted to the ocular surface. Future perspectives include the use of pluripotent stem cells or other adult stem cells to restore the corneal epithelium. However, a measured scientific approach is required to guarantee safety before transplantation can be done in patients. We discussed the growing data on human stromal stem cells, their immune privilege, and their potential to secrete organized collagen lamella that may eventually be useful in tissue engineering. We also summarized the accumulating evidence for the presence of putative stem cells in the corneal endothelium. These cells require specific conditions to show proliferative activity *in vitro* and researchers have already addressed that. Cell therapies for each corneal layer will target a specific disorder, instead of a full or partial thickness corneal transplant, which is the current treatment. Furthermore, one donor cornea will potentially treat multiple patients if the cells are successfully cultivated, and certainly this would have a positive impact on the shortage of donor corneas worldwide.

**REFERENCES**

1 **DelMonte DW**, Kim T. Anatomy and physiology of the cornea. *J Cataract Refract Surg* 2011; **37**: 588-598 [PMID: 21333881 DOI: 10.1016/j.jcrs.2010.12.037]

2 **Dua HS**, Joseph A, Shanmuganathan VA, Jones RE. Stem cell differentiation and the effects of deficiency. *Eye* (Lond) 2003; **17**: 877-885 [PMID: 14631392 DOI: 10.1038/sj.eye.6700573]

3 **Boote C**, Dennis S, Newton RH, Puri H, Meek KM. Collagen fibrils appear more closely packed in the prepupillary cornea: optical and biomechanical implications. *Invest Ophthalmol Vis Sci* 2003; **44**: 2941-2948 [PMID: 12824235 DOI: 10.1167/iovs.03-0131]

4 **Zavala J**, López Jaime GR, Rodríguez Barrientos CA, Valdez-Garcia J. Corneal endothelium: developmental strategies for regeneration. *Eye (Lond)* 2013; **27**: 579-588 [PMID: 23470788 DOI: 10.1038/eye.2013.15]

5 **Bonanno JA**. Molecular mechanisms underlying the corneal endothelial pump. *Exp Eye Res* 2012; **95**: 2-7 [PMID: 21693119 DOI: 10.1016/j.exer.2011.06.004]

6 **Oie Y**, Nishida K. Regenerative medicine for the cornea. *Biomed Res Int* 2013; **2013**: 428247 [PMID: 24396826 DOI: 10.1155/2013/428247]

7 **Kenyon KR**, Tseng SC. Limbal autograft transplantation for ocular surface disorders. *Ophthalmology* 1989; **96**: 709-722; discussion 722-723 [PMID: 2748125 DOI: 10.1016/S0161-6420(89)32833-8]

8 **Schermer A**, Galvin S, Sun TT. Differentiation-related expression of a major 64K corneal keratin in vivo and in culture suggests limbal location of corneal epithelial stem cells. *J Cell Biol* 1986; **103**: 49-62 [PMID: 2424919 DOI: 10.1083/jcb.103.1.49]

9 **Tseng SC**. Concept and application of limbal stem cells. *Eye* (Lond) 1989; **3 (Pt 2)**: 141-157 [PMID: 2695347 DOI: 10.1038/eye.1989.22]

10 **Espana EM**, Grueterich M, Romano AC, Touhami A, Tseng SC. Idiopathic limbal stem cell deficiency. *Ophthalmology* 2002; **109**: 2004-2010 [PMID: 12414406 DOI: 10.1016/s0161-6420(02)01250-2]

11 **Araújo AL**, Ricardo JR, Sakai VN, Barros JN, Gomes JÁ. Impression cytology and in vivo confocal microscopy in corneas with total limbal stem cell deficiency. *Arq Bras Oftalmol* 2013; **76**: 305-308 [PMID: 24232946 DOI: 10.1590/s0004-27492013000500011]

12 **Sacchetti M**, Lambiase A, Cortes M, Sgrulletta R, Bonini S, Merlo D, Bonini S. Clinical and cytological findings in limbal stem cell deficiency. *Graefes Arch Clin Exp Ophthalmol* 2005; **243**: 870-876 [PMID: 15778841 DOI: 10.1007/s00417-005-1159-0]

13 **Elisseeff J**, Madrid MG, Lu Q, Chae JJ, Guo Q. Future perspectives for regenerative medicine in ophthalmology. *Middle East Afr J Ophthalmol* 2013; **20**: 38-45 [PMID: 23580850 DOI: 10.4103/0974-9233.106385]

14 **Tan DT**, Ficker LA, Buckley RJ. Limbal transplantation. *Ophthalmology* 1996; **103**: 29-36 [PMID: 8628556 DOI: 10.1016/S0161-6420(96)30737-9]

15 **Rao SK**, Rajagopal R, Sitalakshmi G, Padmanabhan P. Limbal allografting from related live donors for corneal surface reconstruction. *Ophthalmology* 1999; **106**: 822-828 [PMID: 10201609 DOI: 10.1016/s0161-6420(99)90173-2]

16 **Tsubota K**, Toda I, Saito H, Shinozaki N, Shimazaki J. Reconstruction of the corneal epithelium by limbal allograft transplantation for severe ocular surface disorders. *Ophthalmology* 1995; **102**: 1486-1496 [PMID: 9097796 DOI: 10.1016/S0161-6420(95)30841-X]

17 **Tsai RJ**, Tseng SC. Human allograft limbal transplantation for corneal surface reconstruction. *Cornea* 1994; **13**: 389-400 [PMID: 7995060 DOI: 10.1097/00003226-199409000-00003]

18 **Dua HS**, Azuara-Blanco A. Autologous limbal transplantation in patients with unilateral corneal stem cell deficiency. *Br J Ophthalmol* 2000; **84**: 273-278 [PMID: 10684837 DOI: 10.1136/bjo.84.3.273]

19 **Rao SK**, Rajagopal R, Sitalakshmi G, Padmanabhan P. Limbal autografting: comparison of results in the acute and chronic phases of ocular surface burns. *Cornea* 1999; **18**: 164-171 [PMID: 10090361 DOI: 10.1097/00003226-199903000-00004]

20 **Chen JJ**, Tseng SC. Corneal epithelial wound healing in partial limbal deficiency. *Invest Ophthalmol Vis Sci* 1990; **31**: 1301-1314 [PMID: 1694836]

21 **Chen JJ**, Tseng SC. Abnormal corneal epithelial wound healing in partial-thickness removal of limbal epithelium. *Invest Ophthalmol Vis Sci* 1991; **32**: 2219-2233 [PMID: 1712763]

22 **Titiyal JS,** Sharma N, Agarwal AK, Prakash G, Tandon R, Vajpayee R. Live related versus cadaveric limbal allograft in limbal stem cell deficiency. *Ocul Immunol Inflamm* 2014; **24**: 1-8 [PMID: 25058380 DOI: 10.3109/09273948.2014.902076]

23 **Solomon A**, Ellies P, Anderson DF, Touhami A, Grueterich M, Espana EM, Ti SE, Goto E, Feuer WJ, Tseng SC. Long-term outcome of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency. *Ophthalmology* 2002; **109**: 1159-1166 [PMID: 12045060 DOI: 10.1016/s0161-6420(02)00960-0]

24 **Meallet MA**, Espana EM, Grueterich M, Ti SE, Goto E, Tseng SC. Amniotic membrane transplantation with conjunctival limbal autograft for total limbal stem cell deficiency. *Ophthalmology* 2003; **110**: 1585-1592 [PMID: 12917178 DOI: 10.1016/S0161-6420(03)00503-7]

25 **Santos MS**, Gomes JA, Hofling-Lima AL, Rizzo LV, Romano AC, Belfort R. Survival analysis of conjunctival limbal grafts and amniotic membrane transplantation in eyes with total limbal stem cell deficiency. *Am J Ophthalmol* 2005; **140**: 223-230 [PMID: 16023069 DOI: 10.1016/j.ajo.2005.03.022]

26 **Ivekovic R**, Tedeschi-Reiner E, Novak-Laus K, Andrijevic-Derk B, Cima I, Mandic Z. Limbal graft and/or amniotic membrane transplantation in the treatment of ocular burns. *Ophthalmologica* 2005; **219**: 297-302 [PMID: 16123557 DOI: 10.1159/000086115]

27 **Barreiro TP**, Santos MS, Vieira AC, de Nadai Barros J, Hazarbassanov RM, Gomes JÁ. Comparative study of conjunctival limbal transplantation not associated with the use of amniotic membrane transplantation for treatment of total limbal deficiency secondary to chemical injury. *Cornea* 2014; **33**: 716-720 [PMID: 24831198 DOI: 10.1097/ico.0000000000000139]

28 **Gomes JA**, Romano A, Santos MS, Dua HS. Amniotic membrane use in ophthalmology. *Curr Opin Ophthalmol* 2005; **16**: 233-240 [PMID: 16000896 DOI: 10.1097/01.icu.0000172827.31985.3a]

29 **Lee SH**, Tseng SC. Amniotic membrane transplantation for persistent epithelial defects with ulceration. *Am J Ophthalmol* 1997; **123**: 303-312 [PMID: 9063239 DOI: 10.1016/s0002-9394(14)70125-4]

30 **Gomes JA**, dos Santos MS, Cunha MC, Mascaro VL, Barros Jde N, de Sousa LB. Amniotic membrane transplantation for partial and total limbal stem cell deficiency secondary to chemical burn. *Ophthalmology* 2003; **110**: 466-473 [PMID: 12623806 DOI: 10.1016/S0161-6420(02)01888-2]

31 **Meller D**, Pires RT, Mack RJ, Figueiredo F, Heiligenhaus A, Park WC, Prabhasawat P, John T, McLeod SD, Steuhl KP, Tseng SC. Amniotic membrane transplantation for acute chemical or thermal burns. *Ophthalmology* 2000; **107**: 980-99; discussion 990 [PMID: 10811094 DOI: 10.1016/s0161-6420(00)00024-5]

32 **Sridhar MS**, Bansal AK, Sangwan VS, Rao GN. Amniotic membrane transplantation in acute chemical and thermal injury. *Am J Ophthalmol* 2000; **130**: 134-137 [PMID: 11004281 DOI: 10.1016/s0002-9394(00)00500-6]

33 **Di Pascuale MA**, Espana EM, Liu DT, Kawakita T, Li W, Gao YY, Baradaran-Rafii A, Elizondo A, Raju VK, Tseng SC. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. *Ophthalmology* 2005; **112**: 904-912 [PMID: 15878074 DOI: 10.1016/j.ophtha.2004.11.035]

34 **Honavar SG**, Bansal AK, Sangwan VS, Rao GN. Amniotic membrane transplantation for ocular surface reconstruction in Stevens-Johnson syndrome. *Ophthalmology* 2000; **107**: 975-979 [PMID: 10811093 DOI: 10.1016/s0161-6420(00)00026-9]

35 **Shay E**, Kheirkhah A, Liang L, Sheha H, Gregory DG, Tseng SC. Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis. *Surv Ophthalmol* 2009; **54**: 686-696 [PMID: 19699503 DOI: 10.1016/j.survophthal.2009.03.004]

36 **John T**, Foulks GN, John ME, Cheng K, Hu D. Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. *Ophthalmology* 2002; **109**: 351-360 [PMID: 11825823 DOI: 10.1016/s0161-6420(01)00900-9]

37 **Tamhane A**, Vajpayee RB, Biswas NR, Pandey RM, Sharma N, Titiyal JS, Tandon R. Evaluation of amniotic membrane transplantation as an adjunct to medical therapy as compared with medical therapy alone in acute ocular burns. *Ophthalmology* 2005; **112**: 1963-1969 [PMID: 16198422 DOI: 10.1016/j.ophtha.2005.05.022]

38 **Grueterich M**, Espana EM, Tseng SC. Ex vivo expansion of limbal epithelial stem cells: amniotic membrane serving as a stem cell niche. *Surv Ophthalmol* 2003; **48**: 631-646 [PMID: 14609709 DOI: 10.1016/j.survophthal.2003.08.003]

39 **Pellegrini G**, Traverso CE, Franzi AT, Zingirian M, Cancedda R, De Luca M. Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium. *Lancet* 1997; **349**: 990-993 [PMID: 9100626 DOI: 10.1016/s0140-6736(96)11188-0]

40 **Koizumi N**, Cooper LJ, Fullwood NJ, Nakamura T, Inoki K, Tsuzuki M, Kinoshita S. An evaluation of cultivated corneal limbal epithelial cells, using cell-suspension culture. *Invest Ophthalmol Vis Sci* 2002; **43**: 2114-2121 [PMID: 12091405]

41 **Shortt AJ**, Secker GA, Rajan MS, Meligonis G, Dart JK, Tuft SJ, Daniels JT. Ex vivo expansion and transplantation of limbal epithelial stem cells. *Ophthalmology* 2008; **115**: 1989-1997 [PMID: 18554721 DOI: 10.1016/j.ophtha.2008.04.039]

42 **Rama P**, Matuska S, Paganoni G, Spinelli A, De Luca M, Pellegrini G. Limbal stem-cell therapy and long-term corneal regeneration. *N Engl J Med* 2010; **363**: 147-155 [PMID: 20573916 DOI: 10.1056/NEJMoa0905955]

43 **Schwab IR**, Reyes M, Isseroff RR. Successful transplantation of bioengineered tissue replacements in patients with ocular surface disease. *Cornea* 2000; **19**: 421-426 [PMID: 10928750 DOI: 10.1097/00003226-200007000-00003]

44 **Tsai RJ**, Li LM, Chen JK. Reconstruction of damaged corneas by transplantation of autologous limbal epithelial cells. *N Engl J Med* 2000; **343**: 86-93 [PMID: 10891515 DOI: 10.1097/00132578-200101000-00008]

45 **Nakamura T**, Inatomi T, Sotozono C, Koizumi N, Kinoshita S. Successful primary culture and autologous transplantation of corneal limbal epithelial cells from minimal biopsy for unilateral severe ocular surface disease. *Acta Ophthalmol Scand* 2004; **82**: 468-471 [PMID: 15291944 DOI: 10.1111/j.1395-3907.2004.00285.x]

46 **Kawashima M**, Kawakita T, Satake Y, Higa K, Shimazaki J. Phenotypic study after cultivated limbal epithelial transplantation for limbal stem cell deficiency. *Arch Ophthalmol* 2007; **125**: 1337-1344 [PMID: 17923540 DOI: 10.1016/S0084-392X(08)79075-0]

47 **Li W**, Hayashida Y, He H, Kuo CL, Tseng SC. The fate of limbal epithelial progenitor cells during explant culture on intact amniotic membrane. *Invest Ophthalmol Vis Sci* 2007; **48**: 605-613 [PMID: 17251456 DOI: 10.1167/iovs.06-0514]

48 **Rheinwald JG**, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. *Cell* 1975; **6**: 331-343 [PMID: 1052771 DOI: 10.1016/s0092-8674(75)80001-8]

49 **Tseng SC**, Chen SY, Shen YC, Chen WL, Hu FR. Critical appraisal of ex vivo expansion of human limbal epithelial stem cells. *Curr Mol Med* 2010; **10**: 841-850 [PMID: 21091422 DOI: 10.2174/156652410793937796]

50 **Sangwan VS**, Jain R, Basu S, Bagadi AB, Sureka S, Mariappan I, Macneil S. Transforming ocular surface stem cell research into successful clinical practice. *Indian J Ophthalmol* 2014; **62**: 29-40 [PMID: 24492499 DOI: 10.4103/0301-4738.126173]

51 **Nakamura T**, Inatomi T, Sotozono C, Ang LP, Koizumi N, Yokoi N, Kinoshita S. Transplantation of autologous serum-derived cultivated corneal epithelial equivalents for the treatment of severe ocular surface disease. *Ophthalmology* 2006; **113**: 1765-1772 [PMID: 16905193 DOI: 10.1016/j.ophtha.2006.04.030]

52 **Sangwan VS**, Basu S, Vemuganti GK, Sejpal K, Subramaniam SV, Bandyopadhyay S, Krishnaiah S, Gaddipati S, Tiwari S, Balasubramanian D. Clinical outcomes of xeno-free autologous cultivated limbal epithelial transplantation: a 10-year study. *Br J Ophthalmol* 2011; **95**: 1525-1529 [PMID: 21890785 DOI: 10.1136/bjophthalmol-2011-300352]

53 **Brown KD**, Low S, Mariappan I, Abberton KM, Short R, Zhang H, Maddileti S, Sangwan V, Steele D, Daniell M. Plasma polymer-coated contact lenses for the culture and transfer of corneal epithelial cells in the treatment of limbal stem cell deficiency. *Tissue Eng Part A* 2014; **20**: 646-655 [PMID: 24328453 DOI: 10.1089/ten.TEA.2013.0089]

54 **Gore A**, Horwitz V, Gutman H, Tveria L, Cohen L, Cohen-Jacob O, Turetz J, McNutt PM, Dachir S, Kadar T. Cultivation and characterization of limbal epithelial stem cells on contact lenses with a feeder layer: toward the treatment of limbal stem cell deficiency. *Cornea* 2014; **33**: 65-71 [PMID: 24162749 DOI: 10.1097/ICO.0000000000000002]

55 **Ricardo JR**, Cristovam PC, Filho PA, Farias CC, de Araujo AL, Loureiro RR, Covre JL, de Barros JN, Barreiro TP, dos Santos MS, Gomes JA. Transplantation of conjunctival epithelial cells cultivated ex vivo in patients with total limbal stem cell deficiency. *Cornea* 2013; **32**: 221-228 [PMID: 22580434 DOI: 10.1097/ICO.0b013e31825034be]

56 **Nakamura T**, Endo K, Cooper LJ, Fullwood NJ, Tanifuji N, Tsuzuki M, Koizumi N, Inatomi T, Sano Y, Kinoshita S. The successful culture and autologous transplantation of rabbit oral mucosal epithelial cells on amniotic membrane. *Invest Ophthalmol Vis Sci* 2003; **44**: 106-116 [PMID: 12506062 DOI: 10.1167/iovs.02-0195]

57 **Nakamura T**, Inatomi T, Sotozono C, Amemiya T, Kanamura N, Kinoshita S. Transplantation of cultivated autologous oral mucosal epithelial cells in patients with severe ocular surface disorders. *Br J Ophthalmol* 2004; **88**: 1280-1284 [PMID: 15377551 DOI: 10.1136/bjo.2003.038497]

58 **Inatomi T**, Nakamura T, Kojyo M, Koizumi N, Sotozono C, Kinoshita S. Ocular surface reconstruction with combination of cultivated autologous oral mucosal epithelial transplantation and penetrating keratoplasty. *Am J Ophthalmol* 2006; **142**: 757-764 [PMID: 16989763 DOI: 10.1016/j.ajo.2006.06.004]

59 **Ang LP**, Nakamura T, Inatomi T, Sotozono C, Koizumi N, Yokoi N, Kinoshita S. Autologous serum-derived cultivated oral epithelial transplants for severe ocular surface disease. *Arch Ophthalmol* 2006; **124**: 1543-1551 [PMID: 17102000 DOI: 10.1001/archopht.124.11.1543]

60 **Ma DH**, Kuo MT, Tsai YJ, Chen HC, Chen XL, Wang SF, Li L, Hsiao CH, Lin KK. Transplantation of cultivated oral mucosal epithelial cells for severe corneal burn. *Eye* (Lond) 2009; **23**: 1442-1450 [PMID: 19373264 DOI: 10.1038/eye.2009.60]

61 **Chen HC**, Chen HL, Lai JY, Chen CC, Tsai YJ, Kuo MT, Chu PH, Sun CC, Chen JK, Ma DH. Persistence of transplanted oral mucosal epithelial cells in human cornea. *Invest Ophthalmol Vis Sci* 2009; **50**: 4660-4668 [PMID: 19458337 DOI: 10.1167/iovs.09-3377]

62 **Nakamura T**, Takeda K, Inatomi T, Sotozono C, Kinoshita S. Long-term results of autologous cultivated oral mucosal epithelial transplantation in the scar phase of severe ocular surface disorders. *Br J Ophthalmol* 2011; **95**: 942-946 [PMID: 21097786 DOI: 10.1136/bjo.2010.188714]

63 **Satake Y**, Higa K, Tsubota K, Shimazaki J. Long-term outcome of cultivated oral mucosal epithelial sheet transplantation in treatment of total limbal stem cell deficiency. *Ophthalmology* 2011; **118**: 1524-1530 [PMID: 21571372 DOI: 10.1016/j.ophtha.2011.01.039]

64 **Hirayama M**, Satake Y, Higa K, Yamaguchi T, Shimazaki J. Transplantation of cultivated oral mucosal epithelium prepared in fibrin-coated culture dishes. *Invest Ophthalmol Vis Sci* 2012; **53**: 1602-1609 [PMID: 22323487 DOI: 10.1167/iovs.11-7847]

65 **Sotozono C**, Inatomi T, Nakamura T, Koizumi N, Yokoi N, Ueta M, Matsuyama K, Miyakoda K, Kaneda H, Fukushima M, Kinoshita S. Visual improvement after cultivated oral mucosal epithelial transplantation. *Ophthalmology* 2013; **120**: 193-200 [PMID: 23084239 DOI: 10.1016/j.ophtha.2012.07.053]

66 **Monteiro BG**, Serafim RC, Melo GB, Silva MC, Lizier NF, Maranduba CM, Smith RL, Kerkis A, Cerruti H, Gomes JA, Kerkis I. Human immature dental pulp stem cells share key characteristic features with limbal stem cells. *Cell Prolif* 2009; **42**: 587-594 [PMID: 19614680 DOI: 10.1111/j.1365-2184.2009.00623.x]

67 **Gomes JA**, Geraldes Monteiro B, Melo GB, Smith RL, Cavenaghi Pereira da Silva M, Lizier NF, Kerkis A, Cerruti H, Kerkis I. Corneal reconstruction with tissue-engineered cell sheets composed of human immature dental pulp stem cells. *Invest Ophthalmol Vis Sci* 2010; **51**: 1408-1414 [PMID: 19892864 DOI: 10.1167/iovs.09-4029]

68 **Meyer-Blazejewska EA**, Call MK, Yamanaka O, Liu H, Schlötzer-Schrehardt U, Kruse FE, Kao WW. From hair to cornea: toward the therapeutic use of hair follicle-derived stem cells in the treatment of limbal stem cell deficiency. *Stem Cells* 2011; **29**: 57-66 [PMID: 20957740 DOI: 10.1002/stem.550]

69 **Gu S**, Xing C, Han J, Tso MO, Hong J. Differentiation of rabbit bone marrow mesenchymal stem cells into corneal epithelial cells in vivo and ex vivo. *Mol Vis* 2009; **15**: 99-107 [PMID: 19156227]

70 **Katikireddy KR**, Dana R, Jurkunas UV. Differentiation potential of limbal fibroblasts and bone marrow mesenchymal stem cells to corneal epithelial cells. *Stem Cells* 2014; **32**: 717-729 [PMID: 24022965 DOI: 10.1002/stem.1541]

71 **Reza HM**, Ng BY, Gimeno FL, Phan TT, Ang LP. Umbilical cord lining stem cells as a novel and promising source for ocular surface regeneration. *Stem Cell Rev* 2011; **7**: 935-947 [PMID: 21431286 DOI: 10.1007/s12015-011-9245-7]

72 **Jiang Y**, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. *Nature* 2002; **418**: 41-49 [PMID: 12077603 DOI: 10.1038/nature05812]

73 **Wu J**, Du Y, Mann MM, Funderburgh JL, Wagner WR. Corneal stromal stem cells versus corneal fibroblasts in generating structurally appropriate corneal stromal tissue. *Exp Eye Res* 2014; **120**: 71-81 [PMID: 24440595 DOI: 10.1016/j.exer.2014.01.005]

74 **Maurice DM**. The structure and transparency of the cornea. *J Physiol* 1957; **136**: 263-286 [PMID: 13429485 DOI: 10.1113/jphysiol.1957.sp005758]

75 **Freegard TJ**. The physical basis of transparency of the normal cornea. *Eye* (Lond) 1997; **11 (Pt 4)**: 465-471 [PMID: 9425408 DOI: 10.1038/eye.1997.127]

76 **Funderburgh JL**, Mann MM, Funderburgh ML. Keratocyte phenotype mediates proteoglycan structure: a role for fibroblasts in corneal fibrosis. *J Biol Chem* 2003; **278**: 45629-45637 [PMID: 12933807 DOI: 10.1074/jbc.M303292200]

77 **Long CJ**, Roth MR, Tasheva ES, Funderburgh M, Smit R, Conrad GW, Funderburgh JL. Fibroblast growth factor-2 promotes keratan sulfate proteoglycan expression by keratocytes in vitro. *J Biol Chem* 2000; **275**: 13918-13923 [PMID: 10788517 DOI: 10.1074/jbc.275.18.13918]

78 **Beales MP**, Funderburgh JL, Jester JV, Hassell JR. Proteoglycan synthesis by bovine keratocytes and corneal fibroblasts: maintenance of the keratocyte phenotype in culture. *Invest Ophthalmol Vis Sci* 1999; **40**: 1658-1663 [PMID: 10393032]

79 **Karamichos D**, Funderburgh ML, Hutcheon AE, Zieske JD, Du Y, Wu J, Funderburgh JL. A role for topographic cues in the organization of collagenous matrix by corneal fibroblasts and stem cells. *PLoS One* 2014; **9**: e86260 [PMID: 24465995 DOI: 10.1371/journal.pone.0086260]

80 **Du Y**, Funderburgh ML, Mann MM, SundarRaj N, Funderburgh JL. Multipotent stem cells in human corneal stroma. *Stem Cells* 2005; **23**: 1266-1275 [PMID: 16051989 DOI: 10.1634/stemcells.2004-0256]

81 **Du Y**, Sundarraj N, Funderburgh ML, Harvey SA, Birk DE, Funderburgh JL. Secretion and organization of a cornea-like tissue in vitro by stem cells from human corneal stroma. *Invest Ophthalmol Vis Sci* 2007; **48**: 5038-5045 [PMID: 17962455 DOI: 10.1167/iovs.07-0587]

82 **Du Y**, Carlson EC, Funderburgh ML, Birk DE, Pearlman E, Guo N, Kao WW, Funderburgh JL. Stem cell therapy restores transparency to defective murine corneas. *Stem Cells* 2009; **27**: 1635-1642 [PMID: 19544455 DOI: 10.1002/stem.91]

83 **Pinnamaneni N**, Funderburgh JL. Concise review: Stem cells in the corneal stroma. *Stem Cells* 2012; **30**: 1059-1063 [PMID: 22489057 DOI: 10.1002/stem.1100]

84 **Xu YG**, Xu YS, Huang C, Feng Y, Li Y, Wang W. Development of a rabbit corneal equivalent using an acellular corneal matrix of a porcine substrate. *Mol Vis* 2008; **14**: 2180-2189 [PMID: 19052652]

85 **Fan TJ**, Hu XZ, Zhao J, Niu Y, Zhao WZ, Yu MM, Ge Y. Establishment of an untransfected human corneal stromal cell line and its biocompatibility to acellular porcine corneal stroma. *Int J Ophthalmol* 2012; **5**: 286-292 [PMID: 22773974 DOI: 10.3980/j.issn.2222-3959.2012.03.07]

86 **Zhou Y**, Wu Z, Ge J, Wan P, Li N, Xiang P, Gao Q, Wang Z. Development and characterization of acellular porcine corneal matrix using sodium dodecylsulfate. *Cornea* 2011; **30**: 73-82 [PMID: 20861730 DOI: 10.1097/ICO.0b013e3181dc8184]

87 **Choi HJ**, Kim MK, Lee HJ, Ko JH, Jeong SH, Lee JI, Oh BC, Kang HJ, Wee WR. Efficacy of pig-to-rhesus lamellar corneal xenotransplantation. *Invest Ophthalmol Vis Sci* 2011; **52**: 6643-6650 [PMID: 21743020 DOI: 10.1167/iovs.11-7273]

88 **Ponce Márquez S**, Martínez VS, McIntosh Ambrose W, Wang J, Gantxegui NG, Schein O, Elisseeff J. Decellularization of bovine corneas for tissue engineering applications. *Acta Biomater* 2009; **5**: 1839-1847 [PMID: 19286434 DOI: 10.1016/j.actbio.2009.02.011]

89 **Li N**, Wang X, Wan P, Huang M, Wu Z, Liang X, Liu Y, Ge J, Huang J, Wang Z. Tectonic lamellar keratoplasty with acellular corneal stroma in high-risk corneal transplantation. *Mol Vis* 2011; **17**: 1909-1917 [PMID: 21850165]

90 **Wu Z**, Zhou Q, Duan H, Wang X, Xiao J, Duan H, Li N, Li C, Wan P, Liu Y, Song Y, Zhou C, Huang Z, Wang Z. Reconstruction of auto-tissue-engineered lamellar cornea by dynamic culture for transplantation: a rabbit model. *PLoS One* 2014; **9**: e93012 [PMID: 24705327 DOI: 10.1371/journal.pone.0093012]

91 **Fang XF,** Zhao J, Shi WY, Xie LX. Biocompatibility of acellular corneal stroma and transportation of tissue-engineered corneal epithelium. *Chinese J Ophthalmol* 2008; **44**: 934-942 [PMID: 19176124]

92 **Joyce NC**. Cell cycle status in human corneal endothelium. *Exp Eye Res* 2005; **81**: 629-638 [PMID: 16054624 DOI: 10.1016/j.exer.2005.06.012]

93 **Bourne WM**, Nelson LR, Hodge DO. Central corneal endothelial cell changes over a ten-year period. *Invest Ophthalmol Vis Sci* 1997; **38**: 779-782 [PMID: 9071233 DOI: 10.1016/s0002-9394(14)70810-4]

94 **Jumblatt MM**, Maurice DM, McCulley JP. Transplantation of tissue-cultured corneal endothelium. *Invest Ophthalmol Vis Sci* 1978; **17**: 1135-1141 [PMID: 363636]

95 **Joyce NC**, Harris DL, Mello DM. Mechanisms of mitotic inhibition in corneal endothelium: contact inhibition and TGF-beta2. *Invest Ophthalmol Vis Sci* 2002; **43**: 2152-2159 [PMID: 12091410]

96 **Yu WY**, Sheridan C, Grierson I, Mason S, Kearns V, Lo AC, Wong D. Progenitors for the corneal endothelium and trabecular meshwork: a potential source for personalized stem cell therapy in corneal endothelial diseases and glaucoma. *J Biomed Biotechnol* 2011; **2011**: 412743 [PMID: 22187525 DOI: 10.1155/2011/412743]

97 **Raviola G**. Schwalbe line's cells: a new cell type in the trabecular meshwork of Macaca mulatta. *Invest Ophthalmol Vis Sci* 1982; **22**: 45-56 [PMID: 7056624]

98 **Bylsma SS**, Samples JR, Acott TS, Van Buskirk EM. Trabecular cell division after argon laser trabeculoplasty. *Arch Ophthalmol* 1988; **106**: 544-547 [PMID: 3355425 DOI: 10.1001/archopht.1988.01060130590044]

99 **Acott TS**, Samples JR, Bradley JM, Bacon DR, Bylsma SS, Van Buskirk EM. Trabecular repopulation by anterior trabecular meshwork cells after laser trabeculoplasty. *Am J Ophthalmol* 1989; **107**: 1-6 [PMID: 2912110 DOI: 10.1016/0002-9394(89)90805-2]

100 **Schimmelpfennig BH**. Direct and indirect determination of nonuniform cell density distribution in human corneal endothelium. *Invest Ophthalmol Vis Sci* 1984; **25**: 223-229 [PMID: 6365828]

101 **Amann J**, Holley GP, Lee SB, Edelhauser HF. Increased endothelial cell density in the paracentral and peripheral regions of the human cornea. *Am J Ophthalmol* 2003; **135**: 584-590 [PMID: 12719063 DOI: 10.1016/s0002-9394(02)02237-7]

102 **Bednarz J**, Rodokanaki-von Schrenck A, Engelmann K. Different characteristics of endothelial cells from central and peripheral human cornea in primary culture and after subculture. *In Vitro Cell Dev Biol Anim* 1998; **34**: 149-153 [PMID: 9542652 DOI: 10.1007/s11626-998-0097-7]

103 **Konomi K**, Zhu C, Harris D, Joyce NC. Comparison of the proliferative capacity of human corneal endothelial cells from the central and peripheral areas. *Invest Ophthalmol Vis Sci* 2005; **46**: 4086-4091 [PMID: 16249484 DOI: 10.1167/iovs.05-0245]

104 **Whikehart DR**, Parikh CH, Vaughn AV, Mishler K, Edelhauser HF. Evidence suggesting the existence of stem cells for the human corneal endothelium. *Mol Vis* 2005; **11**: 816-824 [PMID: 16205623]

105 **Senoo T**, Joyce NC. Cell cycle kinetics in corneal endothelium from old and young donors. *Invest Ophthalmol Vis Sci* 2000; **41**: 660-667 [PMID: 10711678]

106 **McGowan SL**, Edelhauser HF, Pfister RR, Whikehart DR. Stem cell markers in the human posterior limbus and corneal endothelium of unwounded and wounded corneas. *Mol Vis* 2007; **13**: 1984-2000 [PMID: 17982423]

107 **Yokoo S**, Yamagami S, Yanagi Y, Uchida S, Mimura T, Usui T, Amano S. Human corneal endothelial cell precursors isolated by sphere-forming assay. *Invest Ophthalmol Vis Sci* 2005; **46**: 1626-1631 [PMID: 15851561 DOI: 10.1167/iovs.04-1263]

108 **Cheong YK**, Ngoh ZX, Peh GS, Ang HP, Seah XY, Chng Z, Colman A, Mehta JS, Sun W. Identification of cell surface markers glypican-4 and CD200 that differentiate human corneal endothelium from stromal fibroblasts. *Invest Ophthalmol Vis Sci* 2013; **54**: 4538-4547 [PMID: 23744997 DOI: 10.1167/iovs.13-1175]

109 **Levis HJ**, Peh GS, Toh KP, Poh R, Shortt AJ, Drake RA, Mehta JS, Daniels JT. Plastic compressed collagen as a novel carrier for expanded human corneal endothelial cells for transplantation. *PLoS One* 2012; **7**: e50993 [PMID: 23226443 DOI: 10.1371/journal.pone.0050993]

110 **Zhu YT**, Hayashida Y, Kheirkhah A, He H, Chen SY, Tseng SC. Characterization and comparison of intercellular adherent junctions expressed by human corneal endothelial cells in vivo and in vitro. *Invest Ophthalmol Vis Sci* 2008; **49**: 3879-3886 [PMID: 18502989 DOI: 10.1167/iovs.08-1693]

111 **Senoo T**, Obara Y, Joyce NC. EDTA: a promoter of proliferation in human corneal endothelium. *Invest Ophthalmol Vis Sci* 2000; **41**: 2930-2935 [PMID: 10967047]

112 **Grottone GT**, Pereira NC, Gomes JÁ. Endothelial keratoplasty: evolution and horizons. *Arq Bras Oftalmol* 2012; **75**: 439-446 [PMID: 23715152 DOI: 10.1590/s0004-27492012000600016]

113 **Kimoto M**, Shima N, Yamaguchi M, Amano S, Yamagami S. Role of hepatocyte growth factor in promoting the growth of human corneal endothelial cells stimulated by L-ascorbic acid 2-phosphate. *Invest Ophthalmol Vis Sci* 2012; **53**: 7583-7589 [PMID: 23081981 DOI: 10.1167/iovs.12-10146]

114 **Peh GS**, Beuerman RW, Colman A, Tan DT, Mehta JS. Human corneal endothelial cell expansion for corneal endothelium transplantation: an overview. *Transplantation* 2011; **91**: 811-819 [PMID: 21358368 DOI: 10.1097/TP.0b013e3182111f01]

115 **Mimura T**, Shimomura N, Usui T, Noda Y, Kaji Y, Yamgami S, Amano S, Miyata K, Araie M. Magnetic attraction of iron-endocytosed corneal endothelial cells to Descemet's membrane. *Exp Eye Res* 2003; **76**: 745-751 [PMID: 12742357 DOI: 10.1016/S0014-4835(03)00057-5]

116 **Mimura T**, Yamagami S, Usui T, Ishii Y, Ono K, Yokoo S, Funatsu H, Araie M, Amano S. Long-term outcome of iron-endocytosing cultured corneal endothelial cell transplantation with magnetic attraction. *Exp Eye Res* 2005; **80**: 149-157 [PMID: 15670793 DOI: 10.1016/j.exer.2004.08.021]

117 **Patel SV**, Bachman LA, Hann CR, Bahler CK, Fautsch MP. Human corneal endothelial cell transplantation in a human ex vivo model. *Invest Ophthalmol Vis Sci* 2009; **50**: 2123-2131 [PMID: 19136716 DOI: 10.1167/iovs.08-2653]

**P-Reviewer:** Dunbar GL **S-Editor:** Tian YL

**L-Editor: E-Editor:**